Researchers at the University of Basel have developed a modular nanorobot capable of autonomous self-assembly, using magnetic propulsion and a replaceable payload capsule to deliver targeted therapies. Published in Advanced Functional Materials, the system utilizes DNA-based “Velcro” to connect components, offering a flexible, reusable platform for medical, industrial, and environmental applications.
How does the modular nanorobot function?
The system operates through a two-module design that mimics the structure of a lunar rocket. According to Prof. Dr. Cornelia Palivan of the University of Basel, the device consists of a magnetic propulsion unit and a payload capsule. The modules are joined by complementary DNA strands, which act as a programmable fastener to ensure stable coupling. This modularity allows researchers to swap payload capsules depending on the required task, a significant shift from previous designs that were often hard-coded for a single function.
Can these nanorobots effectively target cancer cells?
In laboratory tests using HeLa cancer cell lines, the nanorobots demonstrated a precise, localized effect. Dr. Voichita Mihali, the study’s first author, reports that nanorobots loaded with specific enzymes successfully produced an anticancer drug, reducing cell viability to 16 percent within 72 hours. The capsules are equipped with biomolecules that facilitate docking onto specific cell surfaces, ensuring the therapeutic agents are released only where needed.
How does this compare to existing nanorobotic systems?
Most existing nanorobots are designed for singular, fixed tasks, which limits their utility in complex environments. By contrast, the Basel system’s DNA-based modularity allows for “refillable” capsules. This approach mirrors developments in molecular systems engineering, where the goal is to create multifunctional tools that can be repurposed rather than discarded. While the University of Basel team focuses on medical delivery, the ability to separate and recombine modules suggests potential for water purification and industrial chemical processing.
What are the next steps for clinical application?
Despite successful laboratory results, the transition from in-vitro testing to human clinical use remains a long-term objective. The current research, supported by the National Center of Competence in Research – Molecular Systems Engineering and the Swiss Nanoscience Institute, proves the viability of the modular concept. Future iterations will likely focus on scaling production and ensuring the stability of DNA-based connections in complex biological environments, such as the human bloodstream.
Frequently Asked Questions
- Are these robots made of metal? No, they are constructed from biomolecules and nanoparticles, not traditional electronic components.
- Can the nanorobots be reused? Yes. According to the research team, the magnetic propulsion module can be retrieved and the payload capsule can be refilled or swapped.
- What holds the modules together? The modules are joined by DNA-based “Velcro,” which consists of complementary DNA strands that self-assemble.
- Are they ready for human use? No, the technology is currently in the research and laboratory testing phase.
What are your thoughts on the future of nanomedicine? Share your views in the comments below or subscribe to our newsletter for the latest updates on emerging biotechnologies.
